Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

P S Mackie, J L Fisher, H Zhou, P F Choong, P S Mackie, J L Fisher, H Zhou, P F Choong

Abstract

Local growth of osteosarcoma involves destruction of host bone by proteolytic mechanisms and/or host osteoclast activation. Osteoclast formation and activity are regulated by osteoblast-derived factors such as the osteoclast differentiating factor, receptor activator of NF-kappaB ligand (RANKL) and the inhibitor osteoprotegerin (OPG). We have investigated the in vitro effects of bisphosphonates on a clonal rat osteosarcoma cell line. The aminobisphosphonate pamidronate was added to UMR 106-01 cell cultures (10(-8)M to 10(-4)M up to 5 days). The non-aminobisphosphonate clodronate was administered for the same time periods (10(-6)M to 10(-2)M). Cell proliferation, apoptosis and mRNA expression was assessed. Both agents inhibited cell proliferation in a time- and dose-dependent manner. ELISA analysis demonstrated an increase in DNA fragmentation although there was no significant dose-related difference between the doses studied. Bisphosphonate-treated cultures had a greater subpopulation of cells exhibiting morphological changes of apoptosis. Expression of mRNA for osteopontin and RANKL was down-regulated by both agents, while the expression of mRNA for alkaline phosphatase, pro-alpha1(I) collagen and OPG was not altered. Out in vitro work suggests the bisphosphonates not only have direct effects on osteosarcoma cell growth and apoptosis, but also, by altering the relative expression of osteoclast-regulating factors, they may inhibit the activity of osteoclasts and their recruitment.

Copyright 2001 Cancer Research Campaign.

References

    1. Am J Pathol. 1990 Mar;136(3):593-608
    1. Bone Miner. 1989 Apr;6(1):33-43
    1. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473-5
    1. Eur J Cancer. 1991;27(1):37-41
    1. J Clin Invest. 1991 Dec;88(6):2095-105
    1. J Bone Miner Res. 1992 Mar;7(3):335-43
    1. Cancer Treat Rev. 1993 Jan;19(1):79-103
    1. J Bone Miner Res. 1993 Mar;8(3):277-89
    1. J Biol Chem. 1993 May 5;268(13):9901-7
    1. J Clin Invest. 1993 May;91(5):2004-11
    1. J Cell Sci. 1993 Apr;104 ( Pt 4):1013-20
    1. FASEB J. 1993 Dec;7(15):1475-82
    1. Cancer Res. 1994 Feb 1;54(3):832-7
    1. Oncogene. 1994 Aug;9(8):2321-6
    1. Am J Pathol. 1994 Sep;145(3):610-23
    1. Bone Miner. 1994 Aug;26(2):95-107
    1. Ann N Y Acad Sci. 1995 Apr 21;760:223-41
    1. Ann N Y Acad Sci. 1995 Apr 21;760:299-301
    1. Bone. 1995 Apr;16(4 Suppl):317S-327S
    1. Clin Orthop Relat Res. 1995 Mar;(312):19-33
    1. J Bone Miner Res. 1995 Nov;10(11):1666-80
    1. Endocrinology. 1996 Jun;137(6):2324-33
    1. J Clin Invest. 1996 Aug 1;98(3):698-705
    1. Bone. 1996 Oct;19(4):339-45
    1. Cell. 1997 Apr 18;89(2):309-19
    1. Cancer Res. 1997 Sep 15;57(18):3890-4
    1. J Biol Chem. 1997 Oct 3;272(40):25190-4
    1. Br J Haematol. 1997 Sep;98(3):665-72
    1. Cancer. 1997 Oct 15;80(8 Suppl):1674-9
    1. Endocrinology. 1998 Mar;139(3):1329-37
    1. J Clin Oncol. 1998 Mar;16(3):1218-25
    1. J Clin Invest. 1999 Nov;104(10):1363-74
    1. Bone. 1999 Nov;25(5):525-34
    1. Biochem Biophys Res Commun. 2000 Jan 19;267(2):632-7
    1. Br J Cancer. 2000 Apr;82(8):1459-68
    1. Cancer. 2000 Jun 15;88(12 Suppl):2989-94
    1. Nature. 1976 Apr 1;260(5550):436-8
    1. J Biol Chem. 1984 Jan 10;259(1):224-30
    1. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23
    1. Arthritis Rheum. 1988 Jun;31(6):762-8
    1. Bone. 1998 Mar;22(3):233-9
    1. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
    1. J Bone Miner Res. 1998 Apr;13(4):581-9
    1. J Bone Miner Res. 1998 May;13(5):793-802
    1. N Engl J Med. 1998 Aug 6;339(6):357-63
    1. Endocrinology. 1998 Nov;139(11):4743-6
    1. J Bone Miner Res. 1999 Oct;14 Suppl 2:53-65
    1. Biochem Biophys Res Commun. 1988 Nov 30;157(1):166-73
    1. Nature. 1990 May 31;345(6274):442-4

Source: PubMed

3
订阅